Optimal Strategies for Managing Adverse Events with GPRC5D Bispecifics in Multiple Myeloma : Episode 2
Adverse Event Management with BCMA Therapy
Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.
EP: 1.Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
Now Viewing
EP: 2.Adverse Event Management with BCMA Therapy
EP: 3.GPRC5D Therapy: Unique Challenges in Adverse Event Management
EP: 4.Overview of Long-term Follow-up from MonumenTAL-1
EP: 5.Overview of Other GPRC5D Therapy Clinical Trials
EP: 6.Administration and Dosing Management
EP: 7.Clinical Perspective on AE Tolerance
EP: 8.Clinical Experience in Managing AEs in GPRC5D Therapy
EP: 9.Management and Supportive Care for CRS and ICANS in GPRC5D Therapy
EP: 10.Insights on REMS Programs and Strategies for Effective Patient Care
EP: 11.Clinical Scenario: AE Management in a Patient with R/R MM on GPRC5D Therapy
EP: 12.Adverse Event Management Strategies in GPRC5D Therapy
EP: 13.Clinical Scenario: AE Management for Bispecific Therapy in R/R MM
Video content above is prompted by the following:
- What are some common adverse events that you’ve seen in your clinical practice associated with BCMA-directed therapies?
- What mitigation strategies are you implementing to alleviate adverse events?
Recent Videos
Related Content
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Article
Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
